Cargando…
A Case of Pneumocystis jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection
Pneumocystis jirovecii pneumonia is an opportunistic disease usually prevented by trimethoprim-sulfamethoxazole. A 49-year-old HLA-sensitized male with successful late conversion from tacrolimus-based to belatacept-based immunosuppression developed P. jirovecii pneumonia for which he presented sever...
Autores principales: | Perrier, Quentin, Portais, Antoine, Terrec, Florian, Cerba, Yann, Romanet, Thierry, Malvezzi, Paolo, Bedouch, Pierrick, Tetaz, Rachel, Rostaing, Lionel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923707/ https://www.ncbi.nlm.nih.gov/pubmed/33708795 http://dx.doi.org/10.1159/000510842 |
Ejemplares similares
-
Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies
por: Perrier, Quentin, et al.
Publicado: (2021) -
Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response
por: Terrec, Florian, et al.
Publicado: (2021) -
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
por: Kuik, Kelvin Teck-Hong, et al.
Publicado: (2014) -
Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019) -
Efficacy of Plasmapheresis in Nivolumab-Associated ANCA Glomerulonephritis: A Case Report and Pathophysiology Discussion
por: Laamech, Reda, et al.
Publicado: (2021)